CRISPR MEDICINE NEWS | SNIPR BIOME announced this morning that it has dosed the first participants in a clinical trial for SNIPR0001, an orally administered CRISPR-based therapeutic designed to reduce E. coli colonization in the gut to prevent blood infections in patients with cancer.